pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL
Madrigal Pharmaceuticals EU
Madrigal Pharmaceuticals EU Limited
Madrigal Pharmaceuticals EU clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
- Founded
- 2016
- Employees
- 1,071
- Programs
- 16
- Drugs
- 11
- Patents
- 26
Madrigal Pharmaceuticals EU projects
7 ClinicalTrials.gov programs sponsored by Madrigal Pharmaceuticals EU.
Madrigal Pharmaceuticals EU has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
100 mg Resmetirom Tablet
Madrigal Pharmaceuticals EU Limited
Renal Impairment
1 trial -
Atorvastatin
Madrigal Pharmaceuticals EU Limited
Healthy
1 trial -
MGL-3196
Madrigal Pharmaceuticals EU Limited
Healthy
3 trials -
MGL-3196
Madrigal Pharmaceuticals EU Limited
Hepatic Impairment
1 trial -
MGL-3196 Tablet
Madrigal Pharmaceuticals EU Limited
Healthy
1 trial -
Placebo
Madrigal Pharmaceuticals EU Limited
Drug Safety
2 trials -
Simvastatin
Madrigal Pharmaceuticals EU Limited
Healthy
1 trial
Frequently asked questions
How many clinical projects does Madrigal Pharmaceuticals EU have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.